SOURCE: Crown Marketing

January 17, 2013 09:10 ET

Crown Marketing's Japanese Patent Approved and Registered

CHAPEL HILL, NC--(Marketwire - Jan 17, 2013) -  Crown Marketing (OTCQB: CWNM) is pleased to announce its Japanese Patent application, Sustained Release Delivery Systems for Solutes, has been approved and registered.

The intellectual property supporting the Controlled Drug Delivery Technology (CDDT) is comprehensively formulated to allow for the broad application of the technology with regard to the mode of administration, the desired release pattern, the type of compounds employed and the dosage form. 

The technology can be employed to regulate time to first release of drug, the extent of the initial bolus release and the duration of the remaining controlled release. These programmable release profiles may be adjusted for considerations given to the different gastric and intestinal environments. 

The technology is suited for the formulation of nutraceuticals, prescription and OTC drugs. In particular, the patent applications cover drug delivery devices that allow for linear, sustained-release of solutes with adjustable initial release kinetics. 

About The Company:

Crown's Controlled Drug Delivery Technology (CDDT) is a novel controlled-release technology, harnessing the principles diffusion through precise mathematical formulas.

The spectrum and reliability of pharmacokinetic profiles achievable with this technology is superior to currently marketed formulations. Its simple design allows for a high level of flexibility in matching chronotherapeutic requirements. Cost-efficiencies in the commercial manufacturing process, when compared to other drug delivery technologies, may constitute its most important competitive advantage.

The objective of intelligent drug delivery design amounts to maximizing the percent of the time drug plasma levels are within the therapeutic range and avoiding patient exposure to potentially toxic (High) or sub-therapeutic (Low) levels. 

Crown's cost-effective application of controlled delivery technologies will play a major role in the expansion of the pharmaceutical, OTC and nutraceuticals industry through our ability to improve on the performance of immediate release products in a manner tangible to manufacturers and consumers.

More information can be found at:

This release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approvals for anticipated actions.

Contact Information

  • Contact:

    Charles Van Der Ross